Tags

Type your tag names separated by a space and hit enter

Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle.
Metabolism. 2011 Mar; 60(3):394-403.M

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) has been proposed to stimulate mitochondrial biogenesis and fat and glucose metabolism in skeletal muscle. Nicotinamide adenine dinucleotide-dependent histone deacetylase sirtuin 1 (SIRT1) is also thought to play a pivotal role for such metabolic adaptations. The purpose of the present study was to examine the effect of AMPK activation with the administration of AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) to rats on skeletal muscle SIRT1 protein expression as well as peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) and glucose transporter 4 (GLUT4) protein expression and hexokinase activity. The AICAR promoted the phosphorylation of AMPK α-subunit (Thr¹⁷²) and acetyl-coenzyme A carboxylase (Ser⁷⁹) without any change of total AMPK α-subunit or acetyl-coenzyme A carboxylase protein levels in both the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL) muscles. The SIRT1 protein expression increased at 24 hours after administration of AICAR in the EDL muscle but not in the soleus muscle. The PGC-1α protein expression increased in both the soleus and EDL muscles and GLUT4 did in the EDL muscle at 24 hours after an administration of AICAR. The hexokinase activity increased at 18 and 24 hours in the soleus and at 12, 18, and 24 hours in the EDL after an AICAR treatment. These results suggest that short-term AICAR treatment to rats promotes skeletal muscle AMPK phosphorylation and then coincidently increases the SIRT1 protein expression. In addition, such treatment also enhances the PGC-1α and GLUT4 protein contents and hexokinase activity in skeletal muscle.

Authors+Show Affiliations

Faculty of Life Design, Tohoku Institute of Technology, 6 Futatsusawa, Taihaku-ku, Sendai, Miyagi 982-8588, Japan. suwa-m@tohtech.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20362304

Citation

Suwa, Masataka, et al. "Short-term Adenosine Monophosphate-activated Protein Kinase Activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Treatment Increases the Sirtuin 1 Protein Expression in Skeletal Muscle." Metabolism: Clinical and Experimental, vol. 60, no. 3, 2011, pp. 394-403.
Suwa M, Nakano H, Radak Z, et al. Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle. Metab Clin Exp. 2011;60(3):394-403.
Suwa, M., Nakano, H., Radak, Z., & Kumagai, S. (2011). Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle. Metabolism: Clinical and Experimental, 60(3), 394-403. https://doi.org/10.1016/j.metabol.2010.03.003
Suwa M, et al. Short-term Adenosine Monophosphate-activated Protein Kinase Activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Treatment Increases the Sirtuin 1 Protein Expression in Skeletal Muscle. Metab Clin Exp. 2011;60(3):394-403. PubMed PMID: 20362304.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle. AU - Suwa,Masataka, AU - Nakano,Hiroshi, AU - Radak,Zsolt, AU - Kumagai,Shuzo, Y1 - 2010/04/01/ PY - 2009/04/03/received PY - 2010/02/03/revised PY - 2010/03/02/accepted PY - 2010/4/6/entrez PY - 2010/4/7/pubmed PY - 2011/5/11/medline SP - 394 EP - 403 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 60 IS - 3 N2 - Adenosine monophosphate-activated protein kinase (AMPK) has been proposed to stimulate mitochondrial biogenesis and fat and glucose metabolism in skeletal muscle. Nicotinamide adenine dinucleotide-dependent histone deacetylase sirtuin 1 (SIRT1) is also thought to play a pivotal role for such metabolic adaptations. The purpose of the present study was to examine the effect of AMPK activation with the administration of AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) to rats on skeletal muscle SIRT1 protein expression as well as peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) and glucose transporter 4 (GLUT4) protein expression and hexokinase activity. The AICAR promoted the phosphorylation of AMPK α-subunit (Thr¹⁷²) and acetyl-coenzyme A carboxylase (Ser⁷⁹) without any change of total AMPK α-subunit or acetyl-coenzyme A carboxylase protein levels in both the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL) muscles. The SIRT1 protein expression increased at 24 hours after administration of AICAR in the EDL muscle but not in the soleus muscle. The PGC-1α protein expression increased in both the soleus and EDL muscles and GLUT4 did in the EDL muscle at 24 hours after an administration of AICAR. The hexokinase activity increased at 18 and 24 hours in the soleus and at 12, 18, and 24 hours in the EDL after an AICAR treatment. These results suggest that short-term AICAR treatment to rats promotes skeletal muscle AMPK phosphorylation and then coincidently increases the SIRT1 protein expression. In addition, such treatment also enhances the PGC-1α and GLUT4 protein contents and hexokinase activity in skeletal muscle. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/20362304/Short_term_adenosine_monophosphate_activated_protein_kinase_activator_5_aminoimidazole_4_carboxamide_1_β_D_ribofuranoside_treatment_increases_the_sirtuin_1_protein_expression_in_skeletal_muscle_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(10)00077-6 DB - PRIME DP - Unbound Medicine ER -